Brallobarbital
From Wikipedia, the free encyclopedia
 |
|
|
Brallobarbital
|
|
| Systematic (IUPAC) name | |
| 5-(2-bromoprop-2-enyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C10H11BrN2O3 |
| Mol. mass | 287.11 g/mol |
| Synonyms | Brallobarbital, Vesparax |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Brallobarbital is a barbiturate derivative invented in 1964. It has sedative and hypnotic properties, and was used for the treatment of insomnia. Brallobarbital was primarily sold as part of a combination product called Vesparax, composed of 150 mg secobarbital, 50 mg brallobarbital and 50 mg hydroxyzine.[1] The long half-life of this combination of drugs tended to cause a hangover effect the next day,[2] and Vesparax fell into disuse once newer drugs with less side effects had been developed.[3]
[edit] References
- ^ Lhermann J. Clinical application of a new very active hypnotic associating sodium secobarbital, calcium brallobarbital and hydroxyzine (UC-8130). Gazette Medicale de France. 1964 Mar 10;71:961-2. (French)
- ^ Yih TD, Rossum JM. Peculiar pharmacokinetics of brallobarbital as a source of complications in Vesparax intoxication. Xenobiotica. 1976 Jun;6(6):355-62.
- ^ Fischbach R. Efficacy and safety of midazolam and vesparax in treatment of sleep disorders. British Journal of Clinical Pharmacology. 1983;16 Suppl 1:167S-171S.
|
|||||
